Olysio Fact Sheet
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.
TAGline Fall 2015
In Defense of Stringency: In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.
Don’t forget treatment on World Hepatitis Day
On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group urge pharmaceutical companies and the governments of middle-income countries to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.
2015 Pipeline Report
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Gilead: Stop Blocking Access to Hepatitis C Treatment
On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
C U L8ter: Hepatitis C Eradication
Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it, and targets set to address it By Tracy Swan The first global targets for eliminating hepatitis C virus (HCV) will be…
On Targets and Timelines
By Tim Horn With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization…
TAGline Spring 2015
On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
Liver disease from hepatitis C virus (HCV) is one of the leading causes of death around the world. At least 185 million people have been infected and almost 500,000 people die from it each year. The hope for eradicating HCV has recently gained new momentum: effective treatments reaching a 100 percent cure rate in clinical trials are now available.
2014 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.